Single-dose Rituximab Therapy for Refractory Idiopathic Membranous Nephropathy: A
Single-center Experience
#MMPMID28674357
Katsuno T
; Ozaki T
; Kim H
; Kato N
; Suzuki Y
; Akiyama S
; Ishimoto T
; Kosugi T
; Tsuboi N
; Ito Y
; Maruyama S
Intern Med
2017[]; 56
(13
): 1679-1686
PMID28674357
show ga
To date, a recognized treatment for refractory membranous nephropathy (MN) has
not been established. Recently, several reports have indicated the efficacy of
rituximab as a novel treatment option. However, only a few published accounts
exist of rituximab therapy for idiopathic MN (IMN) in the Asian population. We
present the cases of three IMN patients who were treated with single-dose
rituximab after they showed no response to conventional therapies, including
corticosteroids, cyclosporine, cyclophosphamide, mizoribine, and mycophenolate
mofetil. Although one case showed no response, a complete or incomplete remission
was achieved in the other two cases. Rituximab may therefore be a beneficial
treatment option for IMN.
free
free
free
